Unusual non 1a/1b HCV 1 subtypes are mostly prevalent in Sub-Saharan Africa. These variants harbour resistance associated substitutions as natural polymorphisms in the NS5A region and are difficult to characterize and treat. We report the HCV genome sequences from two African subjects with unusual subtype 1 g and 1e treated with the pangenotypic regimen sofosbuvir/velpatasvir with failure in the latter. Sequence analysis of different regions of the HCV genome in a subtype 1 reference panel and use of multiple subtyping tools showed that the NS5A region is the most suitable to detect these unusual HCV subtypes and assist treatment choices.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10096-025-05038-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Modeling Liver Fibrosis Progression in Patients With Viral Hepatitis Using the Machine Learning Tool Subtype and Stage Inference (SuStaIn).
Cureus
February 2025
Department of Radiology, Juntendo University Graduate School of Medicine, Tokyo, JPN.
Background and aim The natural progression of liver fibrosis and its association with biomarker changes have not been fully established in the literature. This study aimed to investigate liver fibrosis progression in patients with hepatitis B virus (HBV) and hepatitis C virus (HCV) infection using a novel machine learning tool called 'Subtype and Stage Inference (SuStaIn).' SuStaIn can identify disease progression patterns and subgroups from cross-sectional biomarker data.
View Article and Find Full Text PDFItalian screening protocol and genotypes characterization for HCV elimination (2022-2023) in Ferrara's province: a real-world study.
Sci Rep
March 2025
AUSL - U.O.S.D. Oncology Screenings, Epidemiology and Health Promotion Programs, Local Health Agency of Ferrara, Corso Giovecca 203, 44121, Ferrara, Italy.
Hepatitis C virus (HCV) is a worldwide health hazard, and in chronic form (nowadays affecting 50 million people - World Health Organization data) can be lethal. To forestall it, preventive screening is a mandatory approach. Since 2021, Italy conducts a national-wide screening program to eliminate the virus from its population.
View Article and Find Full Text PDFSOHO State of the Art Updates and Next Questions: Treatment Options for Marginal Zone Lymphoma.
Clin Lymphoma Myeloma Leuk
February 2025
Clinic of Hematology, EOC, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Institute of Oncology Research, Bellinzona, Switzerland; Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland. Electronic address:
Current classifications identify 3 primary types of marginal zone lymphoma (MZL): extra nodal, splenic, and nodal MZL. MZLs typically have excellent long-term outcomes and often do not require immediate treatment. For asymptomatic patients, active surveillance (watch-and-wait) is the standard approach.
View Article and Find Full Text PDFDirect-acting antiviral treatment outcomes in people infected with endemic compared to epidemic hepatitis C virus subtypes in England.
J Infect
March 2025
UK Health Security Agency, London, UK; National Institute for Health and Care Research Health Protection Research Unit (NIHR HPRU) in Blood Borne and Sexually Transmitted Infections at UCL, London, UK.
Background: Current evidence suggests reduced efficacy of direct-acting antiviral (DAA) treatment among people with endemic Hepatitis C virus (HCV) subtypes rare to high-income countries. We aimed to determine real-world DAA treatment outcomes of people with endemic HCV subtypes in England.
Methods: Data were collected through a national treatment program.
Genotyping and treatment issues with 'unusual' HCV 1 subtypes.
Eur J Clin Microbiol Infect Dis
February 2025
Department of Medical Biotechnologies, University of Siena, Siena, Italy.
Unusual non 1a/1b HCV 1 subtypes are mostly prevalent in Sub-Saharan Africa. These variants harbour resistance associated substitutions as natural polymorphisms in the NS5A region and are difficult to characterize and treat. We report the HCV genome sequences from two African subjects with unusual subtype 1 g and 1e treated with the pangenotypic regimen sofosbuvir/velpatasvir with failure in the latter.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!